AdAlta inked a master services agreement with Cell Therapies, designating the company as its preferred manufacturer to bolster cellular immunotherapy capabilities.

Leveraging AdAlta's i-body technology, the partnership aims to expedite developing and supplying innovative cellular immunotherapies, particularly from Asia, for global patient access.

Cell Therapies will offer services including process development, technology transfer, analytical testing, clinical product manufacturing, supply, and regulatory support.

The collaboration strengthens AdCella, AdAlta's venture with SYNthesis BioVentures, facilitating the entry of Asian cellular immunotherapy innovations into Western-regulated markets.

The initial focus will be on technical feasibility assessments of AdCella's in-licensing candidates.